Baxter Q2 GAAP EPS rises 8% to $0.26; net sales increase 5% to $2.96 billion
BAX•Baxter reports higher Q2 sales and earnings
- Baxter posted Q2 2026 net sales of $2.96 billion, up 5% year over year; GAAP diluted EPS was $0.26.
- GAAP net income from continuing operations rose 11% to $135 million; free cash flow was $181 million.
- Medical Products & Therapies net sales climbed 7% to $2.08 billion; Healthcare Systems & Technologies increased 4% to $801 million.
- CEO Andrew Hider said results beat expectations, helped by an IEEPA tariff refund; Novum IQ LVP shipment and installation hold weighed on Infusion Systems.
- Full-year 2026 outlook was raised to GAAP sales growth of 3%-4%; adjusted diluted EPS was lifted to $1.95-$2.15.
